Patent Application: T-cell receptors target mutant RAS for cancer treatment

ChangeBridge: Patent Apps - Therapeutics (A61P)

Published September 13th, 2023

Detected March 27th, 2026

Summary

The USPTO has published patent application US20260083847A1 concerning T-cell receptors and compositions for treating cancer associated with mutant RAS. The application details methods and compositions involving T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.

View original document View source feed page

What changed

This document is a published patent application (US20260083847A1) from the USPTO, filed on September 13, 2023. It describes T-cell receptors and related compositions designed to target mutant RAS for cancer treatment. The invention focuses on T-cell receptors that bind to specific mutant RAS peptide fragments within particular HLA types, and also includes multispecific antibodies incorporating these T-cell receptors.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in cancer therapeutics and immunotherapy. Companies involved in drug development, particularly in oncology and immunotherapy, should monitor the progress of this and similar patent applications as they may indicate emerging technologies and intellectual property landscapes in the field.

Source document (simplified)

← USPTO Patent Applications

T-CELL RECEPTORS AND COMPOSITIONS THEREOF FOR TARGETING MUTANT RAS

Application US20260083847A1 Kind: A1 Mar 26, 2026

Inventors

Adham Bear, Beatriz Carreno, Gerald Linette, Robert Vonderheide

Abstract

The present invention provides compositions and methods of treating cancer associated with mutant RAS. In certain aspects, the present invention provides T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types. In certain aspects, the present invention provides multispecific (e.g., bispecific) antibodies comprising T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.

CPC Classifications

A61K 40/32 A61K 35/17 A61K 38/00 A61K 40/11 A61K 40/15 A61K 40/42 A61P 35/00 C07K 14/7051 C12N 5/0636 C12N 5/0646 C12N 15/62 C07K 2317/31 C07K 2317/565 C07K 2319/00